Pioneering a new approach to vaccine development and manufacturing using cutting-edge technologies to produce novel synthetic vaccines.
Gylden Pharma has raised $667K in total funding. The most recent round was Grant. The last funding was announced in February 2022.
Gylden Pharma's investors include Innovate UK, Vickers Venture Partners, Trend Investment Group, Department of Health and Social Care.
Gylden Pharma is headquartered in Abingdon, United Kingdom.
Pioneering a new approach to vaccine development and manufacturing using cutting-edge technologies to produce novel synthetic vaccines.
Gylden Pharma is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gylden Pharma — Funding & Investors." VCBacked, February 22, 2022, https://www.vcbacked.co/company/gylden-pharma. Accessed November 15, 2026.
VCBacked. (2022). Gylden Pharma — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/gylden-pharma
{{cite web |title=Gylden Pharma — Funding & Investors |url=https://www.vcbacked.co/company/gylden-pharma |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Gylden Pharma? Request a listing update